|
PAFAH1B2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69779999947828E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64716999999648E-05 |
| Normal-vs-Stage2 |
2.164300E-04 |
| Normal-vs-Stage3 |
2.4967000000764E-07 |
| Normal-vs-Stage4 |
4.99270000009489E-07 |
| Stage1-vs-Stage2 |
7.955800E-01 |
| Stage1-vs-Stage3 |
2.381000E-01 |
| Stage1-vs-Stage4 |
1.035780E-01 |
| Stage2-vs-Stage3 |
5.552200E-01 |
| Stage2-vs-Stage4 |
3.293200E-01 |
| Stage3-vs-Stage4 |
6.042600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.47330000047575E-07 |
| Normal-vs-AfricanAmerican |
5.122100E-02 |
| Normal-vs-Asian |
5.90269999999338E-05 |
| Caucasian-vs-AfricanAmerican |
2.246200E-01 |
| Caucasian-vs-Asian |
6.183800E-01 |
| AfricanAmerican-vs-Asian |
1.820350E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.65229998969363E-09 |
| Normal-vs-Female |
3.26019999996596E-06 |
| Male-vs-Female |
4.065700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.807210E-04 |
| Normal-vs-Age(41-60Yrs) |
3.04970000031268E-07 |
| Normal-vs-Age(61-80Yrs) |
1.29859999975501E-07 |
| Normal-vs-Age(81-100Yrs) |
3.984100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.955580E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.478400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.945600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.810200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.709400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.335000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.459590E-01 |
| Classical-VS-Follicular |
9.387400E-04 |
| Classical-VS-Other |
7.463500E-02 |
| Classical-VS-Normal |
8.14800000000782E-05 |
| Tall-VS-Follicular |
5.015400E-01 |
| Tall-VS-Other |
2.501400E-01 |
| Tall-VS-Normal |
6.06309999999777E-05 |
| Follicular-VS-Other |
4.392200E-01 |
| Follicular-VS-Normal |
2.60529997575532E-09 |
| Other-VS-Normal |
8.781700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.16560000329847E-08 |
| Normal-vs-N1 |
3.98130000001107E-06 |
| N0-vs-N1 |
6.048800E-01 |
|
|
